Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
PRQR
PRQR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PRQR News
ProQR Forms AI Advisory Board and Partners with Ginkgo Bioworks
Apr 08 2026
seekingalpha
PROQR FORMS AI ADVISORY BOARD AND PARTNERS WITH GINKGO BIOWORKS
Apr 08 2026
moomoo
ProQR Reports FY 2025 Financial Highlights
Mar 12 2026
seekingalpha
Butterfly Network and Citius Pharma Boost Biotech Activity in After-Hours Trading
Nov 24 2025
NASDAQ.COM
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Oct 23 2025
NASDAQ.COM
ProQR Secures CTA Approval for AX-0810 and Plans Virtual Investor and Analyst Event on November 3, 2025
Oct 20 2025
Newsfilter
Cantor Fitzgerald Reiterates Overweight on ProQR Therapeutics, Maintains $8 Price Target
Jun 27 2025
Benzinga
JMP Securities Reiterates Market Outperform on ProQR Therapeutics, Maintains $8 Price Target
Jun 27 2025
Benzinga
ProQR Therapeutics Submits Clinical Trial Application for AX-0810, Initiating First-in-Human Study Targeting Cholestatic Liver Diseases
Jun 26 2025
NASDAQ.COM
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
Jun 26 2025
Newsfilter
Oppenheimer Maintains Outperform on ProQR Therapeutics, Lowers Price Target to $9
May 13 2025
Benzinga
ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025
May 01 2025
Newsfilter
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
Apr 14 2025
Newsfilter
ProQR Therapeutics CFO Jurriaan Dekkers Steps Down, Dennis Hom To Succeed; Cristina Lopez Named CMO
Apr 01 2025
NASDAQ.COM
HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Raises Price Target to $12
Mar 14 2025
Benzinga
Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC) and ProQR (PRQR)
Mar 13 2025
Business Insider
Show More News
